Atrial Fibrillation Pipeline Summary

DelveInsight’s, “Atrial Fibrillation - Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atrial Fibrillation: Understanding

Atrial Fibrillation: Overview

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is characterized by rapid, disorganized electrical activity in the atria, resulting in an irregularly irregular ventricular rhythm and ineffective atrial contraction. AF may be classified as paroxysmal, persistent, long-standing persistent, or permanent, depending on its duration and response to treatment. The condition is associated with advancing age, hypertension, heart failure, valvular heart disease, coronary artery disease, obesity, diabetes mellitus, chronic kidney disease, obstructive sleep apnea, and hyperthyroidism.

Patients commonly present with palpitations, fatigue, dyspnea, dizziness, reduced exercise tolerance, chest discomfort, or syncope, although many individuals remain asymptomatic. Atrial fibrillation substantially increases the risk of ischemic stroke, systemic thromboembolism, heart failure, cognitive decline, and cardiovascular mortality.

The pathophysiology of atrial fibrillation involves ectopic electrical activity, predominantly originating from the pulmonary veins, together with atrial structural and electrical remodeling that sustains reentrant circuits. Fibrosis, inflammation, oxidative stress, autonomic nervous system imbalance, atrial dilation, and ion channel abnormalities promote abnormal impulse generation and conduction, resulting in loss of coordinated atrial contraction and blood stasis within the left atrial appendage.

Diagnosis is established by documenting AF on a 12-lead electrocardiogram (ECG) or rhythm strip showing irregular RR intervals without distinct P waves for at least 30 seconds. Additional evaluation includes ambulatory ECG monitoring, transthoracic echocardiography to assess cardiac structure and function, laboratory investigations including thyroid function tests, and transesophageal echocardiography when cardioversion is planned or left atrial thrombus is suspected. Stroke and bleeding risks are assessed using validated clinical risk scores such as CHA?DS?-VASc and HAS-BLED to guide anticoagulation decisions.

Management of atrial fibrillation aims to prevent thromboembolism, control heart rate or restore sinus rhythm, alleviate symptoms, and reduce cardiovascular complications. Oral anticoagulation with direct oral anticoagulants (DOACs) is preferred over warfarin for most eligible patients to reduce the risk of stroke and systemic embolism, while vitamin K antagonists remain indicated in patients with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis. Rate control is achieved using ?-blockers, non-dihydropyridine calcium channel blockers, or digoxin, whereas rhythm control may involve antiarrhythmic drugs, electrical cardioversion, or catheter ablation, particularly in symptomatic patients or those with heart failure. Comprehensive management also includes treatment of modifiable risk factors such as hypertension, obesity, diabetes, sleep apnea, alcohol consumption, and smoking, together with regular follow-up and patient education to improve long-term outcomes.

"Atrial Fibrillation- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.

Atrial Fibrillation Emerging Drugs Chapters

This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs

Milvexian: Bristol-Myers Squibb/ Johnson & Johnson

Milvexian is an investigational, orally administered Factor XIa inhibitor being developed by Bristol Myers Squibb and Johnson & Johnson as a next-generation anticoagulant for the prevention of thromboembolic events in patients with atrial fibrillation. In the Phase III LIBREXIA-AF trial, milvexian is being compared with apixaban to evaluate whether it is at least as effective in reducing the risk of stroke and non-central nervous system systemic embolism while potentially offering a lower risk of bleeding. The randomized, double-blind study enrolled more than 20,000 participants with atrial fibrillation who require chronic anticoagulation, with primary completion anticipated in late 2026.

Etripamil: Milestone Pharmaceuticals

Etripamil is an investigational intranasal, fast-acting L-type calcium channel blocker being developed by Milestone Pharmaceuticals for the acute management of atrial fibrillation with rapid ventricular rate (AF-RVR). In the Phase III ReVeRA-301 trial, patients self-administer 70 mg etripamil nasal spray at the onset of a symptomatic AF-RVR episode, with an optional second dose after 10 minutes if symptoms persist. The randomized, double-blind, placebo-controlled study is evaluating the drug's ability to rapidly reduce ventricular rate within 30 minutes while assessing its safety and tolerability in approximately 750 patients. The study is expected to begin enrollment in 2027, with primary completion anticipated in 2029.

HBI-3000: HUYA Bioscience International

HBI-3000 (sulcardine sulfate) is an investigational intravenous multi-ion channel blocker being developed by HUYABIO International for the rapid pharmacological conversion of recent-onset atrial fibrillation to sinus rhythm. In the Phase II HBI-3000-402 trial, patients with atrial fibrillation of 2–72 hours' duration receive a single 30-minute IV infusion of HBI-3000 in a dose-escalation and placebo-controlled study to evaluate its safety, tolerability, and cardioversion efficacy. The study aims to identify the optimal dose capable of achieving rapid rhythm conversion while minimizing proarrhythmic risk.

Further product details are provided in the report……..

Atrial Fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Atrial Fibrillation
• There are approx. 12+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb and Johnson & Johnson.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial Fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.

Atrial Fibrillation Report Insights

• Atrial Fibrillation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atrial Fibrillation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atrial Fibrillation drugs?
• How many Atrial Fibrillation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial Fibrillation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Johnson & Johnson
• HUYABIO International
• Acesion Pharma
• Novartis
• Milestone Pharmaceuticals
• Thryv Therapeutics
• Bayer

Key Products

• Milvexian
• HBI-3000
• AP31969
• Abelacimab
• Etripamil
• THRV-1268
• BAY 3670549